‘A negative trial, not a failed trial’: Neurocrine axes in-licensed tremor program on phase 2 data

Two years after licensing the asset for $45 million upfront, Neurocrine Biosciences has pulled the plug on the development of NBI-827104 in essential tremor after the failure of a phase 2a clinical trial to make the case for further investment.